Literature DB >> 9816080

Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells.

A Bagnato1, R Tecce, C Moretti, V Di Castro, D Spergel, K J Catt.   

Abstract

The production of endothelin 1 (ET-1) and its receptor-mediated actions on calcium signaling and growth responses were analyzed in human ovarian carcinoma cells. Immuno-reactive ET-1 was released from three of four ovarian tumor cell lines as a function of time in amounts ranging from 56 to 74 fmol/10(6) cells. Reverse-phase HPLC and radioimmuno-assay of conditioned media from tumor cells revealed a single peak coeluting with authentic ET-1. Radioligand binding studies showed that the ET-1-producing cell lines also expressed high-affinity ETA receptors (Kd < 0.1 nM) that ranged in abundance from 2,600 to 43,600 sites/cell. In fura-2-loaded ovarian carcinoma cells, ET-1 induced dose-dependent increases in cytoplasmic Ca2+ concentration. ET-1 also stimulated thymidine incorporation in the three cell lines that expressed ET receptors. In OVCA 433 cells, BQ 123 inhibited the stimulatory actions of ET-1 on thymidine incorporation and cell proliferation, and substantially reduced the basal growth rate of unstimulated ovarian tumor cells. These results demonstrate that ET-1 is produced in ovarian cancer cells and acts as an autocrine growth factor on ETA receptors to stimulate calcium signaling and proliferative responses. Such findings suggest that ET-1 participates in the progression of neoplastic growth in certain ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9816080

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells.

Authors:  A Bagnato; L Rosanò; V Di Castro; A Albini; D Salani; M Varmi; M R Nicotra; P G Natali
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 2.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

Review 4.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

5.  Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.

Authors:  Maria Vaiou; Evanthia Pangou; Panagiotis Liakos; Nikos Sakellaridis; George Vassilopoulos; Konstantinos Dimas; Christos Papandreou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-16       Impact factor: 4.553

6.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

7.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Authors:  William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
Journal:  Invest New Drugs       Date:  2009-09-19       Impact factor: 3.850

Review 8.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 9.  ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.

Authors:  Ruth Warren; Glenn Liu
Journal:  Expert Opin Investig Drugs       Date:  2008-08       Impact factor: 6.206

10.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.